Neurocrine Biosciences had its Relative Strength (RS) Rating upgraded from 70 to 73 Wednesday — a welcome improvement, but still short of the 80 or higher score you look for.
This proprietary rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the best stocks often have an RS Rating north of 80 as they begin their biggest runs. See if Neurocrine Biosciences can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Neurocrine Biosciences is building a cup with handle with a 140.00 buy point. See if the stock can break out in volume at least 40% higher than normal.
The company reported 18% EPS growth in its most recent report, while sales growth came in at 25%.
The company holds the No. 8 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
